Company intelligence / Profile preview

Sloane Pharma

Zug, Zug, Switzerland

Ownership: Private
Development stage: Other

Overview

Sloane Pharma is a specialty pharmaceutical company focused on the development of innovative topical therapies for dermatological conditions. The company utilizes its expertise in drug formulation to create value-added versions of established molecules, aiming to enhance therapeutic outcomes and reduce systemic side effects. Its lead program, SP-01, is a proprietary topical formulation of methotrexate currently being evaluated for the treatment of plaque psoriasis. By leveraging the 505(b)(2) regulatory pathway, Sloane Pharma seeks to bring improved treatments to market more efficiently. The company is headquartered in Zug, Switzerland, and operates as a private entity.

Therapeutic areas: Dermatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Sloane Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sloane Pharma.

Explore the full profile